Cost utility of drugs for multiple sclerosis
نویسندگان
چکیده
منابع مشابه
cost-utility analysis of disease-modifying drugs in relapsing-remitting multiple sclerosis in iran.
background: disease-modifying drugs (dmds) are a significant expenditure for treating multiple sclerosis (ms). however, there is limited report on assessment of the cost-utility of dmds compared with symptom management in the presence of long-term data. this study aimed to assess the lifetime cost-utility from the iranian healthcare perspectives of 4dmds relative to symptom management alone in ...
متن کاملCost-utility analysis of disease-modifying drugs in relapsing-remitting multiple sclerosis in Iran
BACKGROUND Disease-modifying drugs (DMDs) are a significant expenditure for treating multiple sclerosis (MS). However, there is limited report on assessment of the cost-utility of DMDs compared with symptom management in the presence of long-term data. This study aimed to assess the lifetime cost-utility from the Iranian healthcare perspectives of 4DMDs relative to symptom management alone in p...
متن کاملEpigenetic Drugs for Multiple Sclerosis
There is increasing evidence that abnormalities in epigenetic mechanisms of gene expression contribute to the development of multiple sclerosis (MS). Advances in epigenetics have given rise to a new class of drugs, epigenetic drugs. Although many classes of epigenetic drugs are being investigated, at present most attention is being paid to two classes of epigenetic drugs: drugs that inhibit DNA...
متن کاملUtility Estimation of Health Status of Cancer Patients by Mapping for Cost-Utility Analysis
Background: It is important to obtain accurate information about the preferences of people for measuring quality-adjusted life years (QALYs), because it is necessary for cost-utility analysis. In this regard, mapping is a method to access this information. Therefore, the purpose of this study was to map Functional Assessment of Cancer Therapy – General (FACT-G) onto Short Form Six Dimension (SF...
متن کاملDisease-modifying drugs for relapsing-remitting multiple sclerosis and future directions for multiple sclerosis therapeutics.
With the development of effective therapies for multiple sclerosis (MS), therapeutic nihilism, which was so prevalent just 10 years ago, has given way to exuberance and optimism. The current mood is understandable because MS is such a devastating disease. Within 10 years of symptom onset, 50% of patients with MS are unable to carry out household and employment responsibilities; within 15 to 20 ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: BMJ
سال: 2000
ISSN: 0959-8138
DOI: 10.1136/bmj.320.7247.1474